Turbine joins Ginkgo Bioworks’ Technology Network as Inaugural Partner

29 February 2024

Turbine, the leading biological simulation company building a platform for interpreting human biology in silico, is proud to announce that it is an initial member of the Ginkgo Technology Network. Formed by Ginkgo Bioworks (NYSE: DNA) which is building the leading platform for cell programming, the Ginkgo Technology Network is a groundbreaking ecosystem of cutting-edge technology partners, each committed to collaborating with Ginkgo to provide new, integrated capabilities to drive success in customer R&D programs.

  1. The Ginkgo Technology Network brings together over 25 diverse partners across an array of capabilities including AI, genetic medicines, biologics, and manufacturing.
  2. Ginkgo plans to integrate the technological capabilities of its network partners to provide customers with more robust end-to-end solutions to drive successful R&D outcomes across biological end markets.
  3. Based on strong initial customer feedback, Ginkgo expects to add new partners to the network over time, expanding this integrated offering and helping eliminate the siloing and switching costs that limit R&D progress today

“It’s clear that even the best AI models benefit tremendously from access to relevant labeled data and it’s equally clear that experimental designs are dramatically improved with input from AI. I’m grateful to our inaugural network partners for taking this journey with us. The opportunities in biology are too great and the challenges too complex for us to take this journey alone,” said Anna Marie Wagner, SVP, Head of AI, and Head of Corporate Development at Ginkgo Bioworks. “Our goals at Ginkgo are resonant with what Turbine is striving for: bringing more translatability into R&D processes and further increasing the probability of success by better understanding the potential targets for a particular disease.”

Ginkgo Bioworks is uniquely experienced as a systems integrator, offering customers a robust set of services within a unified R&D experience. The parties’ highly compatible platforms and aligned visions about turning engineering into an integral part of biological experiments can pave the way to offering greater value for potential partners through an integrated solution package.

“Integrating with Ginkgo Bioworks to incorporate their high throughput data generation workflows allows us to train Simulated Cells to accurately model complex biological pathways much faster,” said Bob Silverman, Chief Business Officer at Turbine. “This in turn helps our partners understand the most resistant forms of cancer and reveal novel targets, biomarkers and drug combinations to open new fronts in our fight against disease. Our collaboration with Ginkgo is a key step towards embedding biological simulations in every R&D process.”

Concrete details on the collaboration framework and the parties’ integrated solution to follow very soon.

About Turbine

Countless dollars, resources and time get expended globally to research and advance novel therapies that end in clinical failure and no patient benefit. Imagine a world where it is possible to accurately simulate any potential drug’s effect on biological models that may not even be available for lab-based testing, yet truly represent patient biology. Turbine is revolutionizing the status quo.

With machine learning that understands the logic by which human cells make decisions, Turbine’s has built the world’s first predictive simulation of biology. The Simulated Cell™ platform models cellular decision making and facilitates in silico experiments at scales that are impossible in the physical world, empowering the biopharma industry by informing the right experiments that identify and validate disease driving effects.

Turbine’s platform is being validated through past and ongoing collaborations with leading pharma companies such as AstraZeneca, Ono Pharmaceutical, Cancer Research Horizons, and Bayer. In addition, Turbine has received funding from industry leaders such as MSD (Merck & Co, Inc.. Rahway NJ, USA) Global Health Innovation Fund, Accel and MassMutual Ventures among others.

For more information, visit www.turbine.ai or follow Turbine on LinkedIn.

About Ginkgo Bioworks

Ginkgo Bioworks is the leading horizontal platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. Ginkgo’s biosecurity and public health unit, Concentric by Ginkgo, is building global infrastructure for biosecurity to empower governments, communities, and public health leaders to prevent, detect and respond to a wide variety of biological threats. For more information, visit ginkgobioworks.com and concentricbyginkgo.com, read their blog, or follow them on social media channels such as X (@Ginkgo and @ConcentricByGBW), Instagram (@GinkgoBioworks), Threads (@GinkgoBioworks) or LinkedIn.

All rights reserved ©2024 Turbine Ltd.  |   Privacy Policy  |   Created by Art&Board Studio
Read our fresh publication on npj - systems biology and applications!

Network-driven cancer cell avatars for combination discovery and biomarker identification for DNA damage response inhibitors
Read our poster for EACR 2024!
The Simulated Cell™ identifies LIG4 as a novel target in PARPi resistance via the modulation of NHEJ deficiency